RxDoctor Payments Data

Nicholas Skiadas, MD

Cardiovascular Disease · Jacksonville, FLNPI 1043436140

Payments from drug & device makers

$3,833in general payments, 2019–2025

Across 73 payments — averaging $52.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Amgen$576
  • AstraZeneca$398
  • Boston Scientific$393
  • Novartis$283
  • Johnson & Johnson$195
  • plus $818 from 13 others

What the payments were for

  • Food & beverage$3,819100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,833 in reported general payments places this provider in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$13,040
Medicare patients
83
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$266,608
EntrestoSacubitril/Valsartan202$244,492
JardianceEmpagliflozin57$58,989
OzempicSemaglutide32$57,603
FarxigaDapagliflozin Propanediol59$49,122
BrilintaTicagrelor25$20,945
XareltoRivaroxaban13$18,649
Repatha SureclickEvolocumab17$12,475
Rosuvastatin Calcium252$3,473
Atorvastatin Calcium319$2,877
Carvedilol296$2,790
Telmisartan82$2,565
Metoprolol Succinate144$2,387
ClopidogrelClopidogrel Bisulfate150$1,799
Amlodipine Besylate318$1,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$266,608232 claims
NovartisEntresto$283$244,492202 claims
AstraZenecaFarxiga, Brilinta$398$70,06784 claims
Boehringer IngelheimJardiance$17$58,98957 claims
Johnson & JohnsonXarelto$195$18,64913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →